Burger, R. A., Brady, M. F., Bookman, M. A., Monk, B. J., Walker, J. L., Homesley, H. D., . . . Liang, S. X. (2014). Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. American Society of Clinical Oncology.
Citação norma ChicagoBurger, Robert A., et al. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. American Society of Clinical Oncology, 2014.
Citação norma MLABurger, Robert A., et al. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. American Society of Clinical Oncology, 2014.